Targeting Histone Acetylation

Histone Deacetylases (HDACs) and Histone AcetylTransferases (HATs) have proven to be promising targets for drug intervention and there are a number of inhibitors currently being tested in both preclinical and clinical stages. New chemistries and screening tools continue to be developed to probe and modify the biology of these emerging drug targets. Cambridge Healthtech Institute’s inaugural conference on Targeting Histone Acetylation, tracks both the scientific and clinical progress being made to better understand the implications of targeting lysine acetylation in histones.

Preliminary Agenda | Speaker Biographies

UNRAVELING HAT BIOLOGY

KEYNOTE PRESENTATION: Chemical Approaches to Understanding Histone Acetyltransferases

Philip Cole, M.D., Ph.D., Professor and Director, Department of Pharmacology and Molecular Sciences, Johns Hopkins University Medical School

CBP/p300/PCAF/GCN5 vs. Tip60/Myst1 in Foxp3+ Treg Biology and Anti-Tumor Immunity

Wayne W. Hancock, M.D., Ph.D., Professor of Pathology and Chief of Transplant Immunology, Children's Hospital of Philadelphia and University of Pennsylvania

Bioorthogonal Probes to Interrogate Functions of Histone Acetyltransferases

Y. George Zheng, Ph.D., Associate Professor, Department of Pharmaceutical and Biomedical Sciences, University of Georgia